Valuation
- Market cap
- 2,409,072,000
- Revenue TTM
- $828,850,000
- Net income TTM
- $143,260,000
- PE ratio
- 6.58
- Forward PE
- —
- Profit margin
- 17.28%
- Debt to equity
- 0.00
Trading
- Volume
- 1,600
- Avg volume
- 2,268
- Day's range
- $10.16 – $10.24
- Shares out
- 237,710,000
- Stochastic %K
- 22%
- Beta
- 1.36
- Analysts
- Strong Buy
- Price target
- $62.00
Company profile
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immuni...
Show more
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 45 33 26 83 83
- Website
- https://www.bavarian-nordic.com
- Address
- Philip Heymans Alle 3, Hellerup, Denmark
Latest news
No headlines yet.